Cynata Therapeutics Limited (CYP) Earnings Call Transcripts

Cynata Therapeutics Limited's Latest Earnings Call - June 21, 2026

Cynata Therapeutics Limited reported disappointing results from its Phase II graft-versus-host disease (GvHD) and Phase III osteoarthritis trials during the June 2026 earnings call. Both trials failed to meet their primary endpoints, with management expressing significant disappointment and surprise at the outcomes. Revenue and earnings figures were not disclosed, but management indicated that cash reserves are limited, and they will be evaluating options for future funding and trial directions.

Reported metrics

Guidance from management

Management is currently evaluating options for future trials and funding, with no specific guidance provided on timelines or amounts. They emphasized the need to preserve cash and cut costs.

What management said

Yes. Long again, just repeating what Kilian said, we're as disappointed and surprised at the results as anyone else. And we felt like we did everything that we could. And as Kilian explained, the Board is going to meet, in fact, in 15 minutes, 14 minutes, the Board is going to meet to continue this process of trying to understand what the company -- what happened and what the company should do now. We, again, really...

What analysts pressed on

Analysts expressed concerns regarding the unexpected trial results and the high placebo response rates, questioning the trial design and its implications for future studies. There is also apprehension about the company's cash position and ability to fund ongoing and new trials.

Main topics on the call

• Trial Results Disappointment — Both the GvHD and osteoarthritis trials did not meet their primary endpoints, which was unexpected given prior Phase I results. CEO Kilian Kelly stated, "neither of them met the primary endpoints...no statistically signi...
• Safety Profile Maintained — Despite the efficacy failures, both trials reported no safety concerns. Kelly noted, "we saw that the products were safe and well tolerated," which may provide some reassurance to investors.
• High Placebo Response Rates — The osteoarthritis trial saw a surprisingly high response rate in the placebo group, which was 48.1%, compared to an expected 35%. Kelly remarked, "the issue we have there is that it's really indistinguishable from the c...
• Future Pipeline Uncertainty — Management is currently reviewing the future of its pipeline, including the kidney transplant and diabetic foot ulcer trials. Kelly mentioned, "we do need to evaluate our options on that," highlighting the need for strat...

Read the full Cynata Therapeutics Limited transcript (June 21, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 5 Cynata Therapeutics Limited earnings call transcripts on record, spanning May 8, 2024 to June 21, 2026. Based on this history, Cynata Therapeutics Limited reports semi-annually. The most recent call on file is dated June 21, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CYP

Exchange

ASX

Country

AU

Sector

Health Care

Industry

Biotechnology

Calls on record

5

First call

May 8, 2024

Most recent

June 21, 2026

Reporting cadence

semi-annually